stop_circleTerminated/Withdrawn
Carcinoma, Renal Cell
Bayer Identifier:
11547
ClinicalTrials.gov Identifier:
EudraCT Number:
Not Available
EU CT Number:
Not Available
Research Study for Patients with Metastatic Renal Cell Carcinoma
Trial purpose
This study has been designed to study patients diagnosed with advanced renal cell cancer with the primary tumor in place.
Key Participants Requirements
Sex
BothAge
18 YearsTrial summary
Enrollment Goal
1Trial Dates
November 2005 - June 2006Phase
Phase 2Could I Receive a placebo
YesProducts
Nexavar (Sorafenib, BAY43-9006)Accepts Healthy Volunteer
NoWhere to participate
Status | Institution | Location |
---|---|---|
Completed | Dana-Farber Cancer Institute | Boston, 02115-6084, United States |
Primary Outcome
- Best Overall Response Rate (complete and partial response rate)date_rangeTime Frame:During study treatment or within 30 days after termination of active therapyenhanced_encryptionnoSafety Issue:
Secondary Outcome
- Progression-free survivaldate_rangeTime Frame:Last date of tumor assessmentenhanced_encryptionnoSafety Issue:
- Overall response ratedate_rangeTime Frame:Last day of tumor assessementenhanced_encryptionnoSafety Issue:
- Time to responsedate_rangeTime Frame:throughout studyenhanced_encryptionnoSafety Issue:
- Safetydate_rangeTime Frame:all visitsenhanced_encryptionyesSafety Issue:
Trial design
Trial Type
InterventionalIntervention Type
DrugTrial Purpose
TreatmentAllocation
RandomizedBlinding
Double BlindAssignment
Parallel AssignmentTrial Arms
2